2018 Q1 Form 10-K Financial Statement
#000147929018000038 Filed on March 02, 2018
Income Statement
| Concept | 2018 Q1 | 2017 Q4 | 2017 |
|---|---|---|---|
| Revenue | $193.0K | $37.00K | $262.0K |
| YoY Change | 157.33% | -50.67% | -12.67% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $13.62M | $11.89M | $37.40M |
| YoY Change | 75.6% | 67.46% | 28.63% |
| % of Gross Profit | |||
| Research & Development | $22.24M | $21.00M | $80.36M |
| YoY Change | 14.58% | 67.6% | 59.51% |
| % of Gross Profit | |||
| Depreciation & Amortization | $390.0K | $370.0K | $1.468M |
| YoY Change | 9.24% | -2.63% | 1.59% |
| % of Gross Profit | |||
| Operating Expenses | $35.86M | $32.89M | $120.7M |
| YoY Change | 32.0% | 67.55% | 36.35% |
| Operating Profit | -$35.66M | -$120.4M | |
| YoY Change | 31.65% | 36.51% | |
| Interest Expense | $44.00K | $10.00K | $457.0K |
| YoY Change | -77.2% | -200.0% | -57.76% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$319.0K | -$140.0K | -$525.0K |
| YoY Change | 153.17% | 7.69% | -1.87% |
| Pretax Income | -$35.04M | -$35.91M | -$118.3M |
| YoY Change | 29.01% | 33.99% | 32.55% |
| Income Tax | $0.00 | $0.00 | |
| % Of Pretax Income | |||
| Net Earnings | -$35.04M | -$40.62M | -$120.6M |
| YoY Change | 29.02% | 51.54% | 35.04% |
| Net Earnings / Revenue | -18153.89% | -109772.97% | -46025.57% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$974.7K | -$1.139M | -$4.006M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 36.68M shares | 30.93M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q1 | 2017 Q4 | 2017 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $268.8M | $282.9M | $282.9M |
| YoY Change | 42.52% | 52.51% | 52.51% |
| Cash & Equivalents | $69.21M | $282.9M | $282.9M |
| Short-Term Investments | $199.6M | $0.00 | $0.00 |
| Other Short-Term Assets | $4.600M | $444.0K | $2.200M |
| YoY Change | -47.73% | 172.39% | 83.33% |
| Inventory | |||
| Prepaid Expenses | $1.823M | ||
| Receivables | $48.00K | $0.00 | |
| Other Receivables | $0.00 | ||
| Total Short-Term Assets | $273.4M | $285.2M | $285.2M |
| YoY Change | 38.47% | 48.01% | 48.0% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $10.06M | $9.250M | $9.300M |
| YoY Change | -10.18% | -12.61% | -12.26% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $718.0K | $658.0K | $1.200M |
| YoY Change | 232.41% | 31.6% | 9.09% |
| Total Long-Term Assets | $11.36M | $10.49M | $10.50M |
| YoY Change | -5.32% | -10.09% | -10.26% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $273.4M | $285.2M | $285.2M |
| Total Long-Term Assets | $11.36M | $10.49M | $10.50M |
| Total Assets | $284.8M | $295.7M | $295.7M |
| YoY Change | 35.96% | 44.7% | 44.67% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $5.361M | $6.805M | $6.800M |
| YoY Change | -3.8% | 81.27% | 78.95% |
| Accrued Expenses | $11.12M | $12.23M | $11.50M |
| YoY Change | -25.7% | -1.55% | -2.54% |
| Deferred Revenue | $0.00 | ||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $1.000M | $1.900M | $1.900M |
| YoY Change | -71.43% | -45.71% | -45.71% |
| Total Short-Term Liabilities | $23.00M | $20.90M | $20.90M |
| YoY Change | -4.35% | 6.39% | 6.63% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | -100.0% | -100.0% |
| Other Long-Term Liabilities | $25.10M | $0.00 | $6.000M |
| YoY Change | 25000.0% | -100.0% | 3.45% |
| Total Long-Term Liabilities | $25.10M | $0.00 | $6.000M |
| YoY Change | 25000.0% | -100.0% | -22.08% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $23.00M | $20.90M | $20.90M |
| Total Long-Term Liabilities | $25.10M | $0.00 | $6.000M |
| Total Liabilities | $48.14M | $26.85M | $26.90M |
| YoY Change | 56.38% | -1.59% | -1.47% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$577.2M | -$542.2M | |
| YoY Change | 28.63% | 28.61% | |
| Common Stock | $814.1M | $811.0M | |
| YoY Change | 29.74% | 35.47% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $236.6M | $268.8M | $268.8M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $284.8M | $295.7M | $295.7M |
| YoY Change | 35.96% | 44.7% | 44.67% |
Cashflow Statement
| Concept | 2018 Q1 | 2017 Q4 | 2017 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$35.04M | -$40.62M | -$120.6M |
| YoY Change | 29.02% | 51.54% | 35.04% |
| Depreciation, Depletion And Amortization | $390.0K | $370.0K | $1.468M |
| YoY Change | 9.24% | -2.63% | 1.59% |
| Cash From Operating Activities | -$11.14M | -$28.39M | -$95.34M |
| YoY Change | -47.41% | 110.76% | 59.36% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $1.068M | -$490.0K | $2.525M |
| YoY Change | 260.81% | -5.77% | 51.2% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$199.3M | $96.79M | $121.3M |
| YoY Change | 604.56% | -284.96% | -264.32% |
| Cash From Investing Activities | -$200.3M | $96.30M | $118.8M |
| YoY Change | 601.05% | -282.25% | -257.34% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $0.00 | $38.76M | |
| YoY Change | -100.0% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -$2.222M | 158.7M | $195.9M |
| YoY Change | -108.89% | -23780.6% | -7516.5% |
| NET CHANGE | |||
| Cash From Operating Activities | -$11.14M | -28.39M | -$95.34M |
| Cash From Investing Activities | -$200.3M | 96.30M | $118.8M |
| Cash From Financing Activities | -$2.222M | 158.7M | $195.9M |
| Net Change In Cash | -$213.7M | 226.6M | $219.4M |
| YoY Change | 762.85% | -438.27% | -259.02% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$11.14M | -$28.39M | -$95.34M |
| Capital Expenditures | $1.068M | -$490.0K | $2.525M |
| Free Cash Flow | -$12.21M | -$27.90M | -$97.87M |
| YoY Change | -43.17% | 115.44% | 59.14% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2017 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2017 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2017 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | |
| CY2017 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-12-31 | |
| CY2017 | dei |
Document Type
DocumentType
|
10-K | |
| CY2017 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001479290 | |
| CY2018Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
36684782 | shares |
| CY2017 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2017 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
| CY2017 | dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
1999-08-10 | |
| CY2017 | dei |
Entity Information Date To Change Former Legal Or Registered Name
EntityInformationDateToChangeFormerLegalOrRegisteredName
|
2005-04-19 | |
| CY2017Q2 | dei |
Entity Public Float
EntityPublicFloat
|
672000000 | USD |
| CY2017 | dei |
Entity Registrant Name
EntityRegistrantName
|
Revance Therapeutics, Inc. | |
| CY2017 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2017 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
Yes | |
| CY2016Q4 | rvnc |
Accrued Capital Expenditures
AccruedCapitalExpenditures
|
57000 | USD |
| CY2017Q4 | rvnc |
Accrued Capital Expenditures
AccruedCapitalExpenditures
|
302000 | USD |
| CY2016Q4 | rvnc |
Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
|
1271000 | USD |
| CY2017Q4 | rvnc |
Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
|
3189000 | USD |
| CY2016Q4 | rvnc |
Accrued Manufacturing Costs
AccruedManufacturingCosts
|
188000 | USD |
| CY2017Q4 | rvnc |
Accrued Manufacturing Costs
AccruedManufacturingCosts
|
488000 | USD |
| CY2016Q4 | rvnc |
Accrued Milestone Obligations
AccruedMilestoneObligations
|
720000 | USD |
| CY2017Q4 | rvnc |
Accrued Milestone Obligations
AccruedMilestoneObligations
|
1773000 | USD |
| CY2014Q4 | rvnc |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
171542000 | USD |
| CY2015Q4 | rvnc |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
202050000 | USD |
| CY2016Q4 | rvnc |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
64082000 | USD |
| CY2017Q4 | rvnc |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
283476000 | USD |
| CY2015 | rvnc |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
30508000 | USD |
| CY2016 | rvnc |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-137968000 | USD |
| CY2017 | rvnc |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
219394000 | USD |
| CY2017 | rvnc |
Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum
CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum
|
P12M | |
| CY2017 | rvnc |
Common Stock Voting Rights Numberof Votes
CommonStockVotingRightsNumberofVotes
|
1 | votes_per_share |
| CY2016Q4 | rvnc |
Deferred Tax Assets Fixedandintangibleassets
DeferredTaxAssetsFixedandintangibleassets
|
8209000 | USD |
| CY2017Q4 | rvnc |
Deferred Tax Assets Fixedandintangibleassets
DeferredTaxAssetsFixedandintangibleassets
|
7221000 | USD |
| CY2017 | rvnc |
Defined Benefit Plan Ageat Which Benefits Are Provided
DefinedBenefitPlanAgeatWhichBenefitsAreProvided
|
P18Y | |
| CY2015 | rvnc |
Effective Income Tax Rate Reconciliation Saleof Intellectual Property Amount
EffectiveIncomeTaxRateReconciliationSaleofIntellectualPropertyAmount
|
0 | USD |
| CY2016 | rvnc |
Effective Income Tax Rate Reconciliation Saleof Intellectual Property Amount
EffectiveIncomeTaxRateReconciliationSaleofIntellectualPropertyAmount
|
0 | USD |
| CY2017 | rvnc |
Effective Income Tax Rate Reconciliation Saleof Intellectual Property Amount
EffectiveIncomeTaxRateReconciliationSaleofIntellectualPropertyAmount
|
14008000 | USD |
| CY2015 | rvnc |
Effective Income Tax Reconciliation Nondeductibleand Nontaxable Items
EffectiveIncomeTaxReconciliationNondeductibleandNontaxableItems
|
224000 | USD |
| CY2016 | rvnc |
Effective Income Tax Reconciliation Nondeductibleand Nontaxable Items
EffectiveIncomeTaxReconciliationNondeductibleandNontaxableItems
|
832000 | USD |
| CY2017 | rvnc |
Effective Income Tax Reconciliation Nondeductibleand Nontaxable Items
EffectiveIncomeTaxReconciliationNondeductibleandNontaxableItems
|
738000 | USD |
| CY2016Q4 | rvnc |
Financing Lease Obligation Noncurrent Netof Current Portion
FinancingLeaseObligationNoncurrentNetofCurrentPortion
|
1872000 | USD |
| CY2017Q4 | rvnc |
Financing Lease Obligation Noncurrent Netof Current Portion
FinancingLeaseObligationNoncurrentNetofCurrentPortion
|
0 | USD |
| CY2016Q4 | rvnc |
Financing Obligation Current
FinancingObligationCurrent
|
3475000 | USD |
| CY2017Q4 | rvnc |
Financing Obligation Current
FinancingObligationCurrent
|
1872000 | USD |
| CY2017Q4 | rvnc |
Financing Obligation Future Minimum Payments Duein Three Years
FinancingObligationFutureMinimumPaymentsDueinThreeYears
|
900000 | USD |
| CY2015 | rvnc |
Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
|
127000 | USD |
| CY2016 | rvnc |
Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
|
-608000 | USD |
| CY2017 | rvnc |
Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
|
-591000 | USD |
| CY2015 | rvnc |
Interest Expense Capitalized
InterestExpenseCapitalized
|
0 | USD |
| CY2016 | rvnc |
Interest Expense Capitalized
InterestExpenseCapitalized
|
0 | USD |
| CY2016 | rvnc |
Interest Expense Capitalized
InterestExpenseCapitalized
|
0 | USD |
| CY2017 | rvnc |
Interest Expense Capitalized
InterestExpenseCapitalized
|
100000 | USD |
| CY2017 | rvnc |
Interest Expense Capitalized
InterestExpenseCapitalized
|
113000 | USD |
| CY2015 | rvnc |
Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
|
-73476000 | USD |
| CY2016Q1 | rvnc |
Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
|
-19888000 | USD |
| CY2016Q2 | rvnc |
Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
|
-24602000 | USD |
| CY2016Q3 | rvnc |
Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
|
-17978000 | USD |
| CY2016Q4 | rvnc |
Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
|
-26802000 | USD |
| CY2016 | rvnc |
Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
|
-89270000 | USD |
| CY2017Q1 | rvnc |
Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
|
-27156000 | USD |
| CY2017Q2 | rvnc |
Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
|
-26874000 | USD |
| CY2017Q3 | rvnc |
Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
|
-30651000 | USD |
| CY2017Q4 | rvnc |
Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
|
-35906000 | USD |
| CY2017 | rvnc |
Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
|
-120587000 | USD |
| CY2014Q1 | rvnc |
Tenant Improvement Allowance
TenantImprovementAllowance
|
3000000.0 | USD |
| CY2017Q4 | rvnc |
Working Capital Surplus
WorkingCapitalSurplus
|
264300000 | USD |
| CY2017Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
48000 | USD |
| CY2015 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-601000 | USD |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3754000 | USD |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
6805000 | USD |
| CY2016Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
128000 | USD |
| CY2015 | rvnc |
Non Cash Deferred Followon Public Offering Costs
NonCashDeferredFollowonPublicOfferingCosts
|
0 | USD |
| CY2016 | rvnc |
Non Cash Deferred Followon Public Offering Costs
NonCashDeferredFollowonPublicOfferingCosts
|
134000 | USD |
| CY2017 | rvnc |
Non Cash Deferred Followon Public Offering Costs
NonCashDeferredFollowonPublicOfferingCosts
|
251000 | USD |
| CY2017 | rvnc |
Numberof Employees Convertedto Non Employee Consultants
NumberofEmployeesConvertedtoNonEmployeeConsultants
|
2 | employee |
| CY2015 | rvnc |
Proceeds From Issuanceof Follow On Offering
ProceedsFromIssuanceofFollowOnOffering
|
126230000 | USD |
| CY2016 | rvnc |
Proceeds From Issuanceof Follow On Offering
ProceedsFromIssuanceofFollowOnOffering
|
0 | USD |
| CY2017 | rvnc |
Proceeds From Issuanceof Follow On Offering
ProceedsFromIssuanceofFollowOnOffering
|
0 | USD |
| CY2015 | rvnc |
Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount
ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount
|
0 | USD |
| CY2016 | rvnc |
Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount
ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount
|
0 | USD |
| CY2017 | rvnc |
Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount
ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount
|
157468000 | USD |
| CY2017Q4 | rvnc |
Restricted Cash Minimum Balance
RestrictedCashMinimumBalance
|
400000 | USD |
| CY2015 | rvnc |
Stock Issued During Period Value New Issues Follow On Offering
StockIssuedDuringPeriodValueNewIssuesFollowOnOffering
|
126230000 | USD |
| CY2017 | rvnc |
Stock Issued During Period Value New Issues Follow On Offering
StockIssuedDuringPeriodValueNewIssuesFollowOnOffering
|
156933000 | USD |
| CY2017 | rvnc |
Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense
|
62900000 | USD |
| CY2017 | rvnc |
Tax Cutsand Jobs Actof2017 Increase Decreaseto Valuation Allowance
TaxCutsandJobsActof2017IncreaseDecreasetoValuationAllowance
|
-62900000 | USD |
| CY2016 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-1212000 | USD |
| CY2017 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-410000 | USD |
| CY2016Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12418000 | USD |
| CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12225000 | USD |
| CY2016Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
12158000 | USD |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
13531000 | USD |
| CY2016Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-45000 | USD |
| CY2017Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
0 | USD |
| CY2016Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
598630000 | USD |
| CY2017Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
810975000 | USD |
| CY2015 | us-gaap |
Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
82000 | USD |
| CY2016 | us-gaap |
Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
-1000 | USD |
| CY2017 | us-gaap |
Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
18000 | USD |
| CY2015 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
993000 | USD |
| CY2016 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
507000 | USD |
| CY2017 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
573000 | USD |
| CY2015 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
12388000 | USD |
| CY2016 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
11953000 | USD |
| CY2017 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
13230000 | USD |
| CY2015 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
12388000 | USD |
| CY2016 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
11953000 | USD |
| CY2017 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
13230000 | USD |
| CY2015 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD |
| CY2017 | us-gaap |
Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
|
200000 | USD |
| CY2016Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
3648000 | USD |
| CY2016Q4 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
7111000 | USD |
| CY2016 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
9059000 | USD |
| CY2017Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD |
| CY2017Q2 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD |
| CY2017Q3 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD |
| CY2017Q4 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
2927000 | USD |
| CY2016Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
50000 | USD |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
0 | USD |
| CY2016Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
182710000 | USD |
| CY2017Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
236744000 | USD |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
63502000 | USD |
| CY2017 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
2927000 | USD |
| CY2016Q4 | us-gaap |
Assets
Assets
|
204360000 | USD |
| CY2017Q4 | us-gaap |
Assets
Assets
|
295699000 | USD |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
192695000 | USD |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
285211000 | USD |
| CY2016Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
182665000 | USD |
| CY2017Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
236744000 | USD |
| CY2016Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
5000 | USD |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | USD |
| CY2016Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD |
| CY2016Q2 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
1949000 | USD |
| CY2016Q3 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
282896000 | USD |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
185500000 | USD |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
282900000 | USD |
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
2146092 | shares |
| CY2017 | us-gaap |
Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
|
0 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
95000000 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
95000000 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
28648954 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
36516075 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
28648954 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
36516075 | shares |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
29000 | USD |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
37000 | USD |
| CY2015 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-73516000 | USD |
| CY2016 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-89275000 | USD |
| CY2017 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-120542000 | USD |
| CY2016 | us-gaap |
Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
|
0 | USD |
| CY2017Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
3339000 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
139647000 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
106338000 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
4053000 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
6779000 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
4805000 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
5400000 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
2433000 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
2591000 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
159147000 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
128329000 | USD |
| CY2015 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
0 | USD |
| CY2016 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
0 | USD |
| CY2017 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
200000 | USD |
| CY2015 | us-gaap |
Depreciation
Depreciation
|
2000000 | USD |
| CY2015 | us-gaap |
Depreciation
Depreciation
|
1995000 | USD |
| CY2016 | us-gaap |
Depreciation
Depreciation
|
1400000 | USD |
| CY2016 | us-gaap |
Depreciation
Depreciation
|
1445000 | USD |
| CY2017 | us-gaap |
Depreciation
Depreciation
|
1468000 | USD |
| CY2017 | us-gaap |
Depreciation
Depreciation
|
1500000 | USD |
| CY2016Q4 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
2022000 | USD |
| CY2017Q4 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
2613000 | USD |
| CY2015 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-3.02 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.71 | |
| CY2016Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.88 | |
| CY2016Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.64 | |
| CY2016Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.95 | |
| CY2016 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-3.18 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.94 | |
| CY2017Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.90 | |
| CY2017Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.01 | |
| CY2017Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.14 | |
| CY2017 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-4.01 | |
| CY2016Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3121000 | USD |
| CY2017Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
5763000 | USD |
| CY2015 | us-gaap |
Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
|
0 | USD |
| CY2016 | us-gaap |
Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
|
200000 | USD |
| CY2017 | us-gaap |
Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
|
0 | USD |
| CY2015 | us-gaap |
Financing Interest Expense
FinancingInterestExpense
|
344000 | USD |
| CY2016 | us-gaap |
Financing Interest Expense
FinancingInterestExpense
|
406000 | USD |
| CY2017 | us-gaap |
Financing Interest Expense
FinancingInterestExpense
|
271000 | USD |
| CY2015 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-73476000 | USD |
| CY2016 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-89270000 | USD |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-118331000 | USD |
| CY2015 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
0 | USD |
| CY2016 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
0 | USD |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-2256000 | USD |
| CY2015 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-73476000 | USD |
| CY2016 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-89270000 | USD |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-120587000 | USD |
| CY2015 | us-gaap |
Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
|
0 | USD |
| CY2016 | us-gaap |
Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
|
0 | USD |
| CY2017 | us-gaap |
Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
|
0 | USD |
| CY2015 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
24667000 | USD |
| CY2016 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
30053000 | USD |
| CY2017 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-35783000 | USD |
| CY2015 | us-gaap |
Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
|
0 | USD |
| CY2016 | us-gaap |
Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
|
0 | USD |
| CY2017 | us-gaap |
Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
|
62903000 | USD |
| CY2015 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
0 | USD |
| CY2016 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
0 | USD |
| CY2017 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
767000 | USD |
| CY2015 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-24982000 | USD |
| CY2016 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-30352000 | USD |
| CY2017 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-40999000 | USD |
| CY2015 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
607000 | USD |
| CY2016 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
11000 | USD |
| CY2017 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
224000 | USD |
| CY2015 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
516000 | USD |
| CY2016 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
544000 | USD |
| CY2017 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
1858000 | USD |
| CY2015 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-692000 | USD |
| CY2016 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
953000 | USD |
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
2607000 | USD |
| CY2015 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
3179000 | USD |
| CY2016 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
7502000 | USD |
| CY2017 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-565000 | USD |
| CY2015 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-29000 | USD |
| CY2016 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
151000 | USD |
| CY2017 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
403000 | USD |
| CY2015 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
192000 | USD |
| CY2016 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
5591000 | USD |
| CY2017 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-4929000 | USD |
| CY2015 | us-gaap |
Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
|
-200000 | USD |
| CY2016 | us-gaap |
Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
|
-48000 | USD |
| CY2017 | us-gaap |
Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
|
125000 | USD |
| CY2015 | us-gaap |
Interest Expense
InterestExpense
|
1190000 | USD |
| CY2016 | us-gaap |
Interest Expense
InterestExpense
|
1082000 | USD |
| CY2017 | us-gaap |
Interest Expense
InterestExpense
|
457000 | USD |
| CY2015 | us-gaap |
Interest Paid
InterestPaid
|
802000 | USD |
| CY2016 | us-gaap |
Interest Paid
InterestPaid
|
676000 | USD |
| CY2017 | us-gaap |
Interest Paid
InterestPaid
|
299000 | USD |
| CY2015 | us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
231000 | USD |
| CY2016 | us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
1170000 | USD |
| CY2017 | us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
1410000 | USD |
| CY2014Q1 | us-gaap |
Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
|
P36M | |
| CY2014Q1 | us-gaap |
Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
|
P15Y | |
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
27289000 | USD |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
26854000 | USD |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
204360000 | USD |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
295699000 | USD |
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
19647000 | USD |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
20902000 | USD |
| CY2016Q4 | us-gaap |
Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
|
6400000 | USD |
| CY2017Q4 | us-gaap |
Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
|
0 | USD |
| CY2016Q4 | us-gaap |
Loss Contingency Receivable
LossContingencyReceivable
|
5898000 | USD |
| CY2017Q4 | us-gaap |
Loss Contingency Receivable
LossContingencyReceivable
|
0 | USD |
| CY2015 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
142592000 | USD |
| CY2016 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-2642000 | USD |
| CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
195944000 | USD |
| CY2015 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-56415000 | USD |
| CY2016 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-75499000 | USD |
| CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
118792000 | USD |
| CY2015 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-55669000 | USD |
| CY2016 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-59827000 | USD |
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-95342000 | USD |
| CY2015 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-73476000 | USD |
| CY2015 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-73500000 | USD |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19888000 | USD |
| CY2016Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-24602000 | USD |
| CY2016Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17978000 | USD |
| CY2016Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26802000 | USD |
| CY2016 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-89270000 | USD |
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27156000 | USD |
| CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26874000 | USD |
| CY2017Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-30651000 | USD |
| CY2017Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-35906000 | USD |
| CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-120587000 | USD |
| CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-120600000 | USD |
| CY2015 | us-gaap |
Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
|
487000 | USD |
| CY2016 | us-gaap |
Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
|
200000 | USD |
| CY2017 | us-gaap |
Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
|
718000 | USD |
| CY2015 | us-gaap |
Operating Expenses
OperatingExpenses
|
72617000 | USD |
| CY2016 | us-gaap |
Operating Expenses
OperatingExpenses
|
88515000 | USD |
| CY2017 | us-gaap |
Operating Expenses
OperatingExpenses
|
120686000 | USD |
| CY2015 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-72317000 | USD |
| CY2016 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-88215000 | USD |
| CY2017 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-120424000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
38121000 | USD |
| CY2014Q1 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
72800000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
5628000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
6173000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
5996000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
5812000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
14512000 | USD |
| CY2015 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
5300000 | USD |
| CY2016 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
5300000 | USD |
| CY2017 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
5300000 | USD |
| CY2017 | us-gaap |
Operations Commenced Date1
OperationsCommencedDate1
|
2002-06-30 | |
| CY2016Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
163000 | USD |
| CY2017Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
444000 | USD |
| CY2016Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
500000 | USD |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
658000 | USD |
| CY2017 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
100000 | USD |
| CY2015 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-40000 | USD |
| CY2016 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-5000 | USD |
| CY2017 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
45000 | USD |
| CY2016Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
661000 | USD |
| CY2017Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
710000 | USD |
| CY2016Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
100000 | USD |
| CY2017Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
0 | USD |
| CY2015 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-327000 | USD |
| CY2016 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-535000 | USD |
| CY2017 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-525000 | USD |
| CY2017 | us-gaap |
Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
|
0 | USD |
| CY2015 | us-gaap |
Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
|
0 | USD |
| CY2016 | us-gaap |
Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
|
243000 | USD |
| CY2017 | us-gaap |
Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
|
644000 | USD |
| CY2015 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
993000 | USD |
| CY2016 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
507000 | USD |
| CY2017 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
573000 | USD |
| CY2016Q2 | us-gaap |
Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
|
1800000 | USD |
| CY2017Q2 | us-gaap |
Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
|
100000 | USD |
| CY2015 | us-gaap |
Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
|
0 | USD |
| CY2016 | us-gaap |
Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
|
1800000 | USD |
| CY2017 | us-gaap |
Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
|
100000 | USD |
| CY2015 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
54087000 | USD |
| CY2016 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
280681000 | USD |
| CY2017 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
36028000 | USD |
| CY2015 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3328000 | USD |
| CY2016 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1670000 | USD |
| CY2017 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2525000 | USD |
| CY2016Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
7167000 | USD |
| CY2017Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2315000 | USD |
| CY2016Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
978000 | USD |
| CY2017Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1823000 | USD |
| CY2015 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
10021000 | USD |
| CY2016 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | USD |
| CY2017 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
38760000 | USD |
| CY2015 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
|
1000000 | USD |
| CY2016 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
|
207650000 | USD |
| CY2017 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
|
157445000 | USD |
| CY2015 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
0 | USD |
| CY2016 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
2000 | USD |
| CY2017 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
0 | USD |
| CY2015 | us-gaap |
Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
|
0 | USD |
| CY2016 | us-gaap |
Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
|
1000000 | USD |
| CY2017 | us-gaap |
Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
|
0 | USD |
| CY2015 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2753000 | USD |
| CY2016 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1649000 | USD |
| CY2017 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
4569000 | USD |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
22743000 | USD |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
22781000 | USD |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
10585000 | USD |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
9250000 | USD |
| CY2015 | us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
2598000 | USD |
| CY2016 | us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
3541000 | USD |
| CY2017 | us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
3636000 | USD |
| CY2015 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
2652000 | USD |
| CY2016 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
0 | USD |
| CY2017 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
0 | USD |
| CY2016Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2000000 | USD |
| CY2015 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
47529000 | USD |
| CY2016 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
50381000 | USD |
| CY2017 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
80361000 | USD |
| CY2015 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
0 | USD |
| CY2016 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
2000000 | USD |
| CY2017 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
0 | USD |
| CY2016Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
580275 | USD |
| CY2017Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
580275 | USD |
| CY2016Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
580000 | USD |
| CY2017Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
580000 | USD |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-421543000 | USD |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-542167000 | USD |
| CY2015 | us-gaap |
Revenues
Revenues
|
300000 | USD |
| CY2016Q1 | us-gaap |
Revenues
Revenues
|
75000 | USD |
| CY2016Q2 | us-gaap |
Revenues
Revenues
|
75000 | USD |
| CY2016Q3 | us-gaap |
Revenues
Revenues
|
75000 | USD |
| CY2016Q4 | us-gaap |
Revenues
Revenues
|
75000 | USD |
| CY2016 | us-gaap |
Revenues
Revenues
|
300000 | USD |
| CY2017Q1 | us-gaap |
Revenues
Revenues
|
75000 | USD |
| CY2017Q2 | us-gaap |
Revenues
Revenues
|
75000 | USD |
| CY2017Q3 | us-gaap |
Revenues
Revenues
|
75000 | USD |
| CY2017Q4 | us-gaap |
Revenues
Revenues
|
37000 | USD |
| CY2017 | us-gaap |
Revenues
Revenues
|
262000 | USD |
| CY2015 | us-gaap |
Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
|
9831000 | USD |
| CY2017 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
13230000 | USD |
| CY2016Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
122026000 | USD |
| CY2017Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
0 | USD |
| CY2016 | us-gaap |
Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
|
0 | USD |
| CY2017 | us-gaap |
Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
|
0 | USD |
| CY2015 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
25088000 | USD |
| CY2016 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
29075000 | USD |
| CY2017 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
37398000 | USD |
| CY2015 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
12388000 | USD |
| CY2016 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11953000 | USD |
| CY2015 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
318000 | USD |
| CY2016 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
243000 | USD |
| CY2017 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
583000 | USD |
| CY2015 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
10021000 | USD |
| CY2017 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
38157000 | USD |
| CY2015 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2435000 | USD |
| CY2016 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1405000 | USD |
| CY2017 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
3986000 | USD |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
176369000 | USD |
| CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
253252000 | USD |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
177071000 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
268845000 | USD |
| CY2017Q4 | us-gaap |
Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
5000000 | shares |
| CY2017Q4 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
5000000 | shares |
| CY2016Q4 | us-gaap |
Temporary Equity Shares Issued
TemporaryEquitySharesIssued
|
0 | shares |
| CY2017Q4 | us-gaap |
Temporary Equity Shares Issued
TemporaryEquitySharesIssued
|
0 | shares |
| CY2016Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
0 | shares |
| CY2017Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
0 | shares |
| CY2014Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1268000 | USD |
| CY2015Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1537000 | USD |
| CY2016Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1819000 | USD |
| CY2017Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
2577000 | USD |
| CY2015 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
259000 | USD |
| CY2016 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
273000 | USD |
| CY2017 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
758000 | USD |
| CY2015 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
10000 | USD |
| CY2016 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
9000 | USD |
| CY2017 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
0 | USD |
| CY2016 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
29200000 | USD |
| CY2017 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
-30800000 | USD |
| CY2015 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
24340466 | shares |
| CY2016 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
28114784 | shares |
| CY2017 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
30101125 | shares |
| CY2017 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of short and long-term investments. Under the Company's Investment Policy, the Company limits its credit exposure by investing in highly liquid funds and debt obligations of the U.S. government and its agencies with high credit quality. The Company’s cash, cash equivalents, and investments are held in the United States of America. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash, cash equivalents, and investments.</font></div></div> | |
| CY2017 | us-gaap |
Loss Contingency Disclosures
LossContingencyDisclosures
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicis Settlement</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2009, the Company and Medicis Pharmaceutical Corporation, or Medicis, entered into a license agreement granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational, injectable botulinum toxin type A product candidate. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT002 injectable and RT001 topical from Medicis and for consideration payable by the Company to Medicis of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, comprised of (i) an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was paid in 2012, (ii) a Proceeds Sharing Arrangement Payment of </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;"> due upon specified capital raising achievements by the Company, of which </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2013 and </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> in 2014, and (iii) a Product Approval Payment of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be paid upon the achievement of regulatory approval for RT002 injectable or RT001 topical by the Company. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the settlement provisions related to the Proceeds Sharing Arrangement Payment in (ii) above and Product Approval Payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the Product Approval Payment derivative of </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> was determined by updating the timing and probability estimate of the related approval and applying a discount factor assuming a term of </font><font style="font-family:inherit;font-size:10pt;">3.25</font><font style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">1.5%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">9.0%</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company determined the fair value of its liability for the Product Approval Payment was </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">, which was measured by assuming a term of </font><font style="font-family:inherit;font-size:10pt;">2.5 years</font><font style="font-family:inherit;font-size:10pt;">, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">2.0%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">6.5%</font><font style="font-family:inherit;font-size:10pt;">. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2020. The Company did not make any payments under the Product Approval Payment during the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the fair value remeasurements during the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized an aggregate loss of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, an aggregate loss </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, and an aggregate gain of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> | |
| CY2017 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Such management estimates include accruals, stock-based compensation, fair value of derivative liability, impairment of long-lived assets and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.</font></div></div> |
